Cargando…

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study

BACKGROUND: Glycemic variability is associated with the development of diabetic complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 (SGLT2) inhibitors on glycemic variability is controversial. We aimed to examine the effect of dapagliflozin as an add-on therapy to ins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seung-Hwan, Min, Kyung-Wan, Lee, Byung-Wan, Jeong, In-Kyung, Yoo, Soon-Jib, Kwon, Hyuk-Sang, Choi, Yoon-Hee, Yoon, Kun-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164951/ https://www.ncbi.nlm.nih.gov/pubmed/32602273 http://dx.doi.org/10.4093/dmj.2019.0203

Ejemplares similares

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Yang, Hae Kyung, et al.
Publicado: (2019)

Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
por: Han, Kyung Ah, et al.
Publicado: (2023)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Oh, Mi-Ra, et al.
Publicado: (2021)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
por: Moon, Jun Sung, et al.
Publicado: (2023)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
por: Strojek, Krzysztof, et al.
Publicado: (2014)

Add-on unidirectional elastic metamaterial plate cloak
por: Lee, Min Kyung, et al.
Publicado: (2016)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
por: Ferrannini, Ele, et al.
Publicado: (2010)

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
por: Nauck, Michael A., et al.
Publicado: (2011)

Vortioxetine Treatment for Depression in Alzheimer’s Disease: A Randomized, Double-blind, Placebo-controlled Study
por: Jeong, Hye Won, et al.
Publicado: (2022)

Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study
por: Lee, Min-Kyung, et al.
Publicado: (2022)

Efficacy, Safety, and Subject Satisfaction of PrabotulinumtoxinA for Moderate-to-Severe Crow’s Feet: A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
por: Lee, Soo-Kyung, et al.
Publicado: (2023)

Effects of Probiotic NVP-1704 on Mental Health and Sleep in Healthy Adults: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Lee, Hyuk Joo, et al.
Publicado: (2021)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Efficacy and Safety of “URSA Complex” in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
por: Kim, Kwang-Min, et al.
Publicado: (2016)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Subjective Assessment of Diabetes Self-Care Correlates with Perceived Glycemic Control but not with Actual Glycemic Control
por: Ohn, Jung Hun, et al.
Publicado: (2015)

Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
por: Kong, Sung Hye, et al.
Publicado: (2019)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study
por: Bourin, Michel S, et al.
Publicado: (2014)

Blood glucose levels and bodyweight change after dapagliflozin administration
por: Kim, Hyunah, et al.
Publicado: (2021)

THU244 Clinical Factors Affecting Dapagliflozin Response For Glycemic Control And Body Weight Reduction: Post-hoc Analysis Of BEYOND Study
por: Jeung Ahn, Kyu, et al.
Publicado: (2023)

Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
por: Vareesangthip, Kriengsak, et al.
Publicado: (2022)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

ODP544 Cumulative exposure of metabolic syndrome components and the risk of end-stage renal disease in the general population: a nationwide cohort study
por: Yoo, Soon Jib, et al.
Publicado: (2022)

Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study
por: Omranifard, Victoria, et al.
Publicado: (2014)

Safety and tolerability of Korean Red Ginseng in healthy adults: a multicenter, double-blind, randomized, placebo-controlled trial
por: Song, Sang-Wook, et al.
Publicado: (2018)

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population
por: Al AdAwi, Rana Moustafa, et al.
Publicado: (2019)

Effects of Air Purifiers on Patients with Allergic Rhinitis: a Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study
por: Park, Kyung Hee, et al.
Publicado: (2020)

A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis
por: Lee, Myungchul, et al.
Publicado: (2017)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Can asthmatic subjects dive?
por: Adir, Yochai, et al.
Publicado: (2016)

Deep Dive Into the Effects of Food Processing on Limiting Starch Digestibility and Lowering the Glycemic Response
por: Cesbron-Lavau, Gautier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fie2quir7t2shbopb8n0pcedr